Uncovering None And Two Other Promising Small Caps For Your Portfolio

Uncovering None And Two Other Promising Small Caps For Your Portfolio

In a week where the Nasdaq Composite reached a new milestone while most other major indices, including the Russell 2000, saw declines, small-cap stocks have been under pressure amid broader economic uncertainties and rate cut expectations. As investors navigate these volatile conditions, identifying promising small-cap opportunities can be crucial for diversifying portfolios and potentially capitalizing on undervalued assets that may thrive despite market headwinds.

Name

Debt To Equity

Revenue Growth

Earnings Growth

Health Rating

Sugar Terminals

NA

3.14%

3.53%

★★★★★★

Ovostar Union

0.01%

10.19%

49.85%

★★★★★★

Citra Tubindo

NA

11.06%

31.01%

★★★★★★

Prima Andalan Mandiri

0.94%

20.24%

15.28%

★★★★★★

Cardig Aero Services

NA

6.60%

69.79%

★★★★★★

Tianyun International Holdings

10.09%

-5.59%

-9.92%

★★★★★★

CTCI Advanced Systems

30.56%

24.10%

29.97%

★★★★★☆

A2B Australia

15.83%

-7.78%

25.44%

★★★★☆☆

Chongqing Machinery & Electric

27.77%

8.82%

11.12%

★★★★☆☆

Bank MNC Internasional

18.72%

4.80%

43.63%

★★★★☆☆

Click here to see the full list of 600 stocks from our Undiscovered Gems With Strong Fundamentals screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Simply Wall St Value Rating: ★★★★★☆

Overview: Oyak Yatirim Menkul Degerler A.S. offers research, brokerage, portfolio management, corporate finance, and fund operation services for capital market instruments in Turkey with a market cap of TRY10.19 billion.

Operations: Oyak Yatirim derives its revenue primarily from services related to research, brokerage, portfolio management, corporate finance, and fund operations. The company’s financial performance is reflected in its market capitalization of TRY10.19 billion.

Oyak Yatirim Menkul Degerler showcases a compelling profile with its debt-to-equity ratio improving from 137.7% to 98.1% over five years, indicating better financial health. Despite having more cash than total debt, recent earnings reports highlight challenges, with a net loss of TRY 6.48 million in Q3 2024 compared to TRY 290.94 million profit last year and a nine-month net loss of TRY 284.01 million against last year’s income of TRY 479.28 million. The price-to-earnings ratio stands at an attractive 8.2x versus the market’s 16.3x, suggesting potential undervaluation amidst industry outperformance in earnings growth at 11%.

IBSE:OYYAT Earnings and Revenue Growth as at Dec 2024

Simply Wall St Value Rating: ★★★★★★

More From Author

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Dalfen Industrial Expands Northeast Portfolio with Acquisition of Class A Warehouse in Central New Jersey

Dalfen Industrial Expands Northeast Portfolio with Acquisition of Class A Warehouse in Central New Jersey

Leave a Reply

Your email address will not be published. Required fields are marked *